Literature DB >> 15609286

A case of hemoglobin SC disease with cold agglutinin-induced hemolysis.

Hiroto Inaba1, Terrence L Geiger, Olga E Lasater, Winfred C Wang.   

Abstract

Children with sickle cell disease commonly require red blood cell (RBC) transfusion. We report the first case of hemoglobin (Hb) SC disease with development of severe anemia induced by cold agglutinin hemolysis after Mycoplasma infection. Complete blood count (CBC) showed falsely decreased RBC count and hematocrit and falsely elevated MCV and MCHC. Peripheral blood smear showed RBC clumping at room temperature; this disappeared after warming to 37 degrees C. Anti C3b-C3d was present on red cells, and indirect antiglobulin test revealed a circulating cold agglutinin. Furthermore, anti-Mycoplasma pneumoniae IgM antibody was detected in serum. Careful evaluation of CBCs and peripheral blood smears is required in cases of worsening anemia among sickle cell patients and consideration should be given to cold hemagglutinin disease as an etiology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15609286     DOI: 10.1002/ajh.20244

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

1.  The role of infection in the pathogenesis of vaso-occlusive crisis in patients with sickle cell disease.

Authors:  Sagir G Ahmed
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-07-08       Impact factor: 2.576

2.  Mycoplasma pneumonia with persistent lymphadenopathy and severe cold agglutinin haemolysis.

Authors:  Mit Shah; Sajid Khan; Kenneth Chan
Journal:  Respir Med Case Rep       Date:  2016-10-17

3.  Cold agglutinin disease in sepsis: A rare entity.

Authors:  Ravinder Garg; Neetu Kukar; Sukhminder Jit Singh Bajwa; Shaminder Kaur
Journal:  J Basic Clin Pharm       Date:  2015-06

Review 4.  Insights into the pathogenesis of Mycoplasma pneumoniae (Review).

Authors:  Jun He; Mihua Liu; Zhufeng Ye; Tianping Tan; Xinghui Liu; Xiaoxing You; Yanhua Zeng; Yimou Wu
Journal:  Mol Med Rep       Date:  2016-09-23       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.